Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mutation Study Suggests Changes to Clinical Management

By LabMedica International staff writers
Posted on 08 Aug 2019
Lynch syndrome (LS) results from pathogenic variants in the mismatch repair (MMR) genes and is the most common hereditary cancer syndrome, affecting an estimated 1 in 300 individuals.

Pathogenic variants in each of the MMR genes path_MLH1, path_MSH2, path_MSH6, and path_PMS2 result in different risks for cancers in organs including the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas, and upper urinary tract.

A multinational group led the Oslo University Hospital (Oslo, Norway) carried out a prospective observational study without a control group in which they counted cancers detected during follow-up in 6,350 carriers of path_MMR variants. More...
Before merging the previous and validation cohorts, all variants in the previous cohort were reassessed and only cases with variants now scored as class 4 or class 5 were included. Follow-up data for these cases were also updated, adding more follow-up years when possible.

The team reported that the lifetime risk of colorectal cancer for MLH1 and MSH2 pathogenic mutation carriers in the cohort was 50%, despite patients being followed with colonoscopy and having suspicious polyps removed. Both men and women with these mutations saw higher risks of urinary tract and upper gastrointestinal cancers at older ages, with men with MSH2 mutations in particular showing an increased risk for prostate cancer. Breast cancer risk was similar across all four LS genes, representing a relatively insignificantly increase compared with reported general population risks.

The combined analysis did find, though, that female carriers of MLH1, MSH2, and MSH6 mutations have a rapidly rising risk of gynecological cancers starting at 40 years of age. Importantly MSH6 did not correspond to a similarly high risk of colorectal cancer in males, just 18%. This suggests a sex-limited trait with relatively low penetrance in males that could lead to families escaping detection by family history.

The investigators proposed a redefinition of the term Lynch syndrome to encompass four clinically distinct inherited cancer risk syndromes. More specifically, they argue, PMS2 mutation carriers should not be grouped together with carriers of MLH1 and MSH2 pathogenic variants, considering that both genetic counseling and clinical management would differ for the two groups. MSH6 mutations may also justify specific surveillance strategies tailored to this genotype. The study was published on July 24, 2019, in the journal Genetics in Medicine.

Related Links:
Oslo University Hospital


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.